Clinical Trial Update: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors [Phase 1]

View source ↗

Summary

This update reports that the Phase 1 trial of FHD-609 for advanced synovial sarcoma and SMARCB1-deficient tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smarcb1-deficient Tumors
• Synovial Sarcoma

Drugs mentioned

• FHD-609

Snippet

Sponsor: Foghorn Therapeutics Inc. | Conditions: Advanced Synovial Sarcoma | Phase 1 | Status: TERMINATED